推荐产品
product name
BL21(DE3)感受态细胞 - Novagen, BL21(DE3) is a chemically competent E. coli cell suitable for transformation and high level protein expression using a T7 RNA polymerase-IPTG induction system.
生物源
Escherichia coli
品質等級
製造商/商標名
Novagen®
儲存條件
OK to freeze
avoid repeated freeze/thaw cycles
增長模式
adherent or suspension
形態學
rod shaped
技術
microbiological culture: suitable
細胞轉化
transformation efficiency: >2×107 cfu/μg
運輸包裝
dry ice
儲存溫度
−70°C
一般說明
BL21(DE3)是一种化学感受态大肠埃希菌细胞,适用于使用T7 RNA聚合酶IPTG诱导系统进行转化和高水平蛋白质表达。
将DNA质粒转化为大肠埃希菌的常用方法是使用化学感受态细胞。尽管可以在实验室中制备感受态细胞,但使用Novagen制备的感受态细胞可获得更高的效率、重现性和便利性。Novagen感受态细胞代表了可用于蛋白质表达的最广泛选择。每个Novagen感受态细胞株都经过表型和纯度验证,并保证转化效率。如(DE3)所示,
T7表达菌株是噬菌体DE3的溶原性菌。这些宿主携带由lacUV5启动子控制的T7 RNA聚合酶基因的无染色体拷贝。此类菌株适用于利用IPTG作为诱导剂,从在适当的T7表达载体中克隆的靶基因生产蛋白质。
自1990年首次引入BL21以来,它一直是蛋白质表达的金标准。由于缺乏lon和ompT蛋白酶,BL21及其衍生物是许多应用的理想选择。
T7表达菌株是噬菌体DE3的溶原性菌。这些宿主携带由lacUV5启动子控制的T7 RNA聚合酶基因的无染色体拷贝。此类菌株适用于利用IPTG作为诱导剂,从在适当的T7表达载体中克隆的靶基因生产蛋白质。
自1990年首次引入BL21以来,它一直是蛋白质表达的金标准。由于缺乏lon和ompT蛋白酶,BL21及其衍生物是许多应用的理想选择。
该产品包含转基因物种(GMO)。在欧盟范围内,转基因物种分别受欧洲议会和理事会的2001/18/EC和2009/41/EC指令及其成员国中国家所实施规范的约束。该法规规定我们有义务索取您以及处理转基因生物的机构的相关信息。请点击这里获得最终用户声明(EUD)表格。
成分
0.4 ml1 ml成分
•2 × 0.2 ml5 × 0.2 mlBL21(DE3)感受态细胞
•2 × 2 ml4 × 2 mlSOC培养基
•2 ng2 ng测试质粒
•2 × 0.2 ml5 × 0.2 mlBL21(DE3)感受态细胞
•2 × 2 ml4 × 2 mlSOC培养基
•2 ng2 ng测试质粒
警告
毒性:多个毒性值,请参阅MSDS(O)
法律資訊
NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
10 - Combustible liquids
水污染物質分類(WGK)
WGK 2
其他客户在看
International journal of molecular sciences, 25(2) (2024-01-23)
Biofilm dispersal contributes to bacterial spread and disease transmission. However, its exact mechanism, especially that in the pathogen Mycobacterium tuberculosis, is unclear. In this study, the cellulase activity of the M. tuberculosis Rv0062 protein was characterized, and its effect on
Current biology : CB, 32(23), 5189-5199 (2022-11-18)
LIM-domain-containing repeat (LCR) proteins are recruited to strained actin filaments within stress fibers in cultured cells,1,2,3 but their roles at cell-cell junctions in living organisms have not been extensively studied. Here, we show that the Caenorhabditis elegans LCR proteins TES-1/Tes
Structure (London, England : 1993), 29(12), 1382-1396 (2021-08-18)
The COVID-19 pandemic has resulted in 198 million reported infections and more than 4 million deaths as of July 2021 (covid19.who.int). Research to identify effective therapies for COVID-19 includes: (1) designing a vaccine as future protection; (2) de novo drug
Structure (London, England : 1993), 28(11), 1238-1248 (2020-08-20)
A host of new technologies are under development to improve the quality and reproducibility of cryoelectron microscopy (cryoEM) grid preparation. Here we have systematically investigated the preparation of three macromolecular complexes using three different vitrification devices (Vitrobot, chameleon, and a
Molecular cell, 72(2), 263-274 (2018-09-25)
Antibiotic-resistant bacterial pathogens pose an urgent healthcare threat, prompting a demand for new medicines. We report the mode of action of the natural ansamycin antibiotic kanglemycin A (KglA). KglA binds bacterial RNA polymerase at the rifampicin-binding pocket but maintains potency
商品
Colony PCR reagents and our colony PCR protocol using REDExtract-N-Amp™ PCR ReadyMix™ and JumpStart™ REDTaq® PCR ReadyMix™ reagents.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门